Precision metabolic therapy for propionic acidemia

Boopathi Subramaniyan1, Fang Lu2, Huan Li1

  • 1Surgical Research Lab, Department of Surgery, Cooper University Health Care, Camden, NJ 08103, USA.

Insights

Propionic acidemia (PA) is a metabolic disorder where toxic buildup impairs cellular function. Combination therapies targeting short-chain fatty acid metabolism and CoA homeostasis offer a promising new strategy for treating PA.

Area of Science:

  • Biochemistry
  • Metabolic Disorders
  • Genetics

Background:

  • Propionic acidemia (PA) is a rare genetic disorder caused by propionyl-CoA carboxylase deficiency.
  • Accumulation of propionyl-CoA and toxic metabolites disrupts cellular metabolism, leading to mitochondrial dysfunction and multi-organ pathology.
  • Current treatments like dietary restriction and supportive therapies have suboptimal long-term outcomes.

Purpose of the Study:

  • To review current understanding of PA pathophysiology and treatment limitations.
  • To explore emerging therapeutic strategies, including gene-based and small-molecule approaches.
  • To propose a novel combination therapy targeting short-chain fatty acid metabolism and CoA homeostasis.

Main Methods:

  • Literature review of PA pathophysiology, current management, and novel therapeutic strategies.
  • Analysis of metabolic pathways affected by propionyl-CoA accumulation.
  • Conceptualization of a precision metabolic therapy combining multiple interventions.

Main Results:

  • Propionyl-CoA accumulation disrupts TCA cycle flux, ammonia detoxification, and promotes oxidative stress.
  • Existing treatments face challenges with tolerability, efficacy, and extrahepatic disease.
  • Gene therapy and small molecules show promise but require further development.
  • Emerging strategies focus on metabolic reprogramming and restoring CoA pools.

Conclusions:

  • Rational combination therapy targeting multiple metabolic nodes is proposed as a superior strategy for PA.
  • This approach aims to restore metabolic balance by addressing propionyl-CoA burden and CoA homeostasis.
  • Precision metabolic therapy holds potential for improved long-term outcomes in PA patients.

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Protein Import into the Peroxisomes01:27

Protein Import into the Peroxisomes

Cells contain membrane-bound organelles called peroxisomes that oxidize organic molecules by transferring hydrogen atoms to oxygen, producing hydrogen peroxide. Peroxisomes enzymatically convert the released hydrogen peroxide into water and oxygen.
Peroxisomal Protein Import:
Peroxisomes lack the genetic machinery required to code for their own proteins. Hence, most peroxisomal membrane, lumenal and transmembrane proteins are synthesized in the cytoplasm or ER and transported to the peroxisome...
Pyruvate Oxidation01:15

Pyruvate Oxidation

After glycolysis, the charged pyruvate molecules enter the mitochondria via active transport and undergo three enzymatic reactions. These reactions ensure that pyruvate can enter the next metabolic pathway so that energy stored in the pyruvate molecules can be harnessed by the cells.
First, the enzyme pyruvate dehydrogenase removes the carboxyl group from pyruvate and releases it as carbon dioxide. The stripped molecule is then oxidized and releases electrons, which are then picked up by NAD+...